Cogent Biosciences
Cogent Biosciences Inc is an American clinical-stage biopharmaceutical company developing targeted precision therapies for genetically defined diseases. The company's lead candidate, bezuclastinib, is a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation driving systemic mastocytosis and advanced gastrointestinal stromal tumors. Main revenue drivers currently comprise investment capital financing, research grants, and potential milestone licensing payments as Phase III clinical trials advance. Cogent Biosciences targets hematologists, medical oncologists, clinical trial networks, and systemic mastocytosis patients across North America and Europe. The company holds an innovative position in precision kinase inhibitor development for rare genetic disorders. Headquartered in Waltham, Massachusetts, Cogent Biosciences Inc is listed on the Nasdaq Stock Market.
7 of the funds FundTelligence covers report a position in Cogent Biosciences.
- Legal name
- Cogent Biosciences Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
Funds holding Cogent Biosciences
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.76 % (full portfolio disclosed, September 2026)
- SEB Läkemedelsfond — SEB · 0.49 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.35 % (full portfolio disclosed, October 2026)
- Swedbank Robur Healthcare — Swedbank · 0.24 % (full portfolio disclosed, October 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.05 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.04 % (partially disclosed portfolio, June 2026)